| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37e28d2705329f706a00a24481bbfb13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f42cfae908af4e4691e38ee3ee173f19 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-197
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198 |
| filingDate |
2010-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7375b7ccdc7fecf0429f22fc9d63f23a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_926e80901f815cf5ed4ef4fd87f8b460 |
| publicationDate |
2010-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010115291-A1 |
| titleOfInvention |
Hemodialysis and peritoneal dialysis solutions comprising one or more creatine compounds |
| abstract |
The present invention relates to a haemodialysis solution or concentrate thereof comprising creatine compound(s) and the use of creatine compound(s) for preparing a dialysis solution or concentrate thereof. Furthermore, the present invention is directed to a method for preparing creatine-containing dialysis solutions and concentrates. In addition, the present invention is directed to a method for treating patients with dialysis dependent renal failure with creatine compounds and to provide a variety of significant health benefits and improvement of life quality parameters for dialysis patients. This is achieve by supporting and improving the physiological functions of the patients organs and cells via creatine compounds delivery to the patients, and by protecting organs and cells (specifically including blood cells) of these patients from deleterious effects of a variety of endogenous or exogenous cellular stressors that are linked to the disease state or to the clinical treatment modalities. Furthermore in peritoneal dialysis solutions creatine can be used as an osmotic agent preventing side effects caused by high glucose supplementation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3003358-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102973599-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2587908-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2010275752-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11077238-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3723766-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-022387-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102973599-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8791078-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011009601-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019150323-A1 |
| priorityDate |
2009-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |